Encompass Health Corp (EHC) - Q3 2024 10-Q Summary
Business Context and Reporting Period
This report covers the quarterly period ended September 30, 2024. Encompass Health Corporation is the nation's largest owner and operator of inpatient rehabilitation hospitals, operating 165 facilities across 38 states and Puerto Rico. The company operates a mix of wholly-owned hospitals and joint ventures, with significant concentrations in Florida and Texas.
Key Financial Metrics
| Metric (in millions) | Q3 2024 | Q3 2023 | 9M 2024 | 9M 2023 |
|---|---|---|---|---|
| Net Operating Revenues | $1,351.0 | $1,206.9 | $3,968.2 | $3,554.4 |
| Net Income (Total) | $147.1 | $113.4 | $432.4 | $343.9 |
| Net Income Attributable to EHC | $108.2 | $85.3 | $334.8 | $264.4 |
| Diluted EPS (Attributable to EHC) | $1.06 | $0.84 | $3.28 | $2.62 |
| Operating Cash Flow (9M) | $724.0 | $649.8 | - | - |
| Adjusted EBITDA (9M) | $814.1 | $716.1 | - | - |
| Total Debt (Long-term + Current) | $2,577.5 | $2,712.6 | - | - |
| Cash & Equivalents | $147.8 | $69.1 | - | - |
Note: Operating margins (Operating Expenses as % of Revenue) improved to 84.5% in Q3 2024 from 85.1% in Q3 2023.
Material Changes vs. Prior Period
- Revenue Growth: Net operating revenues increased 11.9% in Q3 and 11.6% for the nine months ended September 30, 2024, driven primarily by volume growth (8.8% increase in discharges for Q3) and new hospital openings.
- Profitability: Net income attributable to Encompass Health rose 26.8% in Q3 and 26.6% for the nine-month period, outpacing revenue growth due to operational leverage and lower revenue reserves for bad debt.
- Debt Reduction: The company redeemed $150 million of its 5.75% Senior Notes due 2025 in August 2024. Additionally, on October 22, 2024, the company issued notice to redeem another $100 million of the same notes in November 2024.
- Impairment Charge: The nine-month period included a $10.4 million impairment charge related to the closure of a joint venture hospital in Eau Claire, Wisconsin, which reduced net income by approximately $1.8 million attributable to Encompass Health.
- Joint Venture Expansion: In July 2024, the company expanded a joint venture with Piedmont Healthcare, contributing a hospital in Augusta, Georgia, which resulted in a $22.9 million post-tax gain and $90 million in capital contributions from the partner.
Guidance, Outlook, and Risks
- Outlook: Management remains optimistic about long-term prospects due to demographic trends (aging population). The company expects the 2025 Medicare Final Rule to result in a net increase to payment rates of approximately 3.3% effective October 1, 2024.
- Capital Allocation: The board increased the quarterly dividend to $0.17 per share (from $0.15) and reset the stock repurchase authorization to $500 million. Approximately $498 million remains available for repurchases as of September 30, 2024.
- Capital Expenditures: The company expects to spend between $595 million and $625 million on capital expenditures in 2024, with approximately $185-$195 million designated as nondiscretionary maintenance.
- Key Risks:
- Regulatory & Reimbursement: Significant exposure to Medicare regulations, including the Review Choice Demonstration (RCD) which subjects 29% of Medicare claims to 100% pre-claim review in certain states.
- Staffing: Continued challenges in recruiting and retaining nurses and therapists, leading to increased labor costs and reliance on contract labor.
- Legal: Ongoing exposure to qui tam (whistleblower) lawsuits under the False Claims Act, which are common in the healthcare industry.
Investor Verification Checklist
- Debt Maturities: Verify the impact of the upcoming $100 million note redemption in November 2024 on liquidity and cash reserves.
- Medicare RCD Impact: Monitor the financial impact of the 100% pre-claim review process in Alabama and potential expansion to other states on cash collection cycles.
- Joint Venture Economics: Review the profitability and integration of new joint ventures (e.g., Piedmont, Baptist Health) versus wholly-owned assets.
- Labor Cost Trends: Track the ratio of contract labor to internal FTEs and the effectiveness of strategies to reduce sign-on and shift bonuses.
- Capital Expenditure Execution: Confirm the timeline and cost of de novo projects (e.g., Houston, Athens, Fort Myers) against the $595-$625 million budget.